Stockscreener 앱 받기
444.64
7.83%
32.29
시간 외 거래:
445.80
1.16
+0.26%
전일 마감가:
$412.35
열려 있는:
$406.22
하루 거래량:
1.25M
Relative Volume:
3.35
시가총액:
$9.87B
수익:
-
순이익/손실:
$-518.67M
주가수익비율:
-17.70
EPS:
-25.12
순현금흐름:
$-438.32M
1주 성능:
+3.60%
1개월 성능:
+0.37%
6개월 성능:
+40.94%
1년 성능:
+34.20%
1일 변동 폭
$405.00
$469.95
1주일 범위
$393.61
$469.95
52주 변동 폭
$265.00
$469.95
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
명칭
Madrigal Pharmaceuticals Inc
전화
404-380-9263
주소
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
MDGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
444.64 | 9.19B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-02-28 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | 재확인 | H.C. Wainwright | Buy |
| 2024-06-28 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-06-11 | 개시 | Wolfe Research | Outperform |
| 2024-04-22 | 개시 | BofA Securities | Underperform |
| 2024-03-15 | 업그레이드 | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | 개시 | Citigroup | Buy |
| 2024-02-26 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | 재확인 | Oppenheimer | Outperform |
| 2022-12-19 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-19 | 재확인 | Piper Sandler | Overweight |
| 2022-12-19 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | 재개 | Goldman | Buy |
| 2020-11-24 | 재개 | Evercore ISI | Outperform |
| 2020-11-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-05 | 개시 | BMO Capital Markets | Market Perform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-01-30 | 개시 | Canaccord Genuity | Buy |
| 2020-01-09 | 업그레이드 | UBS | Neutral → Buy |
| 2019-11-07 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-06-10 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Outperform |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-12-12 | 개시 | B. Riley FBR | Neutral |
| 2018-11-19 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-09-04 | 개시 | Citigroup | Buy |
| 2018-08-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2018-06-28 | 개시 | Raymond James | Mkt Perform |
모두보기
Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스
Madrigal Pharmaceuticals Inc (MDGL) Q3 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Madrigal Pharma Bets On Rezdiffra For Future Growth - Finimize
Madrigal Pharmaceuticals stock hits all-time high at 463.92 USD - Investing.com
Earnings call transcript: Madrigal Pharma Q3 2025 falls short of EPS forecast - Investing.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock extend growth storyAnalyst Upgrade & Free Expert Verified Stock Movement Alerts - newser.com
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded by Bank of America to Neutral Rating - MarketBeat
Madrigal Pharmaceuticals Q3 Net Loss Widens, Revenue Rises - MarketScreener
Madrigal Pharmaceuticals Q3 2025 Earnings: EPS Misses, Revenue S - GuruFocus
Madrigal Pharmaceuticals (MDGL) Reports Strong Q3 Revenue Boost - GuruFocus
Madrigal: Q3 Earnings Snapshot - San Antonio Express-News
Madrigal Pharma Q3 revenue rises on Rezdiffra demand - TradingView
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates - The Manila Times
Madrigal Pharmaceuticals (NASDAQ: MDGL) reports $287.3M Q3 sales, up from $62.2M - Stock Titan
How Madrigal Pharmaceuticals Inc. (YDO1) stock performs in volatility spikes2025 Market WrapUp & Daily Price Action Insights - newser.com
Visual analytics tools that track Madrigal Pharmaceuticals Inc. performanceJuly 2025 Setups & Daily Stock Trend Watchlist - newser.com
Can Madrigal Pharmaceuticals Inc. stock beat market expectations this quarterOptions Play & Weekly Chart Analysis and Guides - newser.com
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.Long Setup & Accurate Technical Buy Alerts - newser.com
Will Madrigal Pharmaceuticals Inc. stock gain from lower inflationMarket Risk Report & Smart Investment Allocation Tips - newser.com
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.Portfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stockDay Trade & Weekly Return Optimization Plans - newser.com
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Chart based exit strategy for Madrigal Pharmaceuticals Inc.July 2025 Snapshot & Daily Profit Maximizing Tips - newser.com
Madrigal Pharmaceuticals (MDGL) Upgraded to Neutral by BofA on R - GuruFocus
Madrigal Pharmaceuticals upgraded at BofA on Rezdiffra uptake - Seeking Alpha
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potential2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
MDGL: B of A Securities Upgrades Madrigal Pharmaceuticals to Neu - GuruFocus
MDGL: B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals stock rating upgraded by BofA on strong launch - Investing.com Canada
BofA Upgrades Madrigal Pharmaceuticals to Neutral From Underperform, Price Target is $445 - MarketScreener
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsJuly 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthEarnings Risk Summary & Free High Return Stock Watch Alerts - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownWeekly Risk Summary & Weekly Market Pulse Alerts - newser.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Can Madrigal Pharmaceuticals Inc. stock hit record highs againJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthJuly 2025 Institutional & Weekly High Potential Stock Alerts - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis tools2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Madrigal Pharmaceuticals Inc. stock chart pattern explained2025 Technical Patterns & Risk Managed Investment Signals - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Research Analysts Offer Predictions for MDGL FY2025 Earnings - MarketBeat
Is it too late to sell Madrigal Pharmaceuticals Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - newser.com
Madrigal Pharmaceuticals Inc (MDGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):